01When to call for pain instead of heat
Abdominal or pelvic pain, distention, and weight gain are the OHSS early list. A hot face without those signs is usually the vasomotor row.
If heat arrives with new spots or blur, stop for the eye. The vision-stop probe and the pulse both say discontinue.
02How flushes usually leave after the course
Adverse reactions have usually been mild and transient and most disappeared promptly after treatment stopped. That is the file's general AE sentence, and it fits many flush stories.
Zuclomiphene can linger more than a month. A late warm spell after the last tablet can still happen. Persistent severe pain is not that story. See clomiphene 50 mg.
03Why a second tablet the same day is wrong
Overdose-range symptoms from using more than the recommended dose include vasomotor flushes plus visual blur and ovarian pain. Stacking 50 mg because you are already flushing can add the worse rows.
The labelled 100 mg day, when written, is two 50 mg tablets once daily for five days on a later course, not an extra tablet tonight.
04What other effects sat next to flushes
Events under 1% included rash, mood change, insomnia, hair loss, dizziness, and weight gain or loss. Postmarketing lists add irritability and anxiety. Common and uncommon are not the same urgency.
Breast discomfort at 2.1% can coexist with flushes. Neither one licenses a sixth tablet.
05How often vasomotor flushes showed in trials
Only ovarian enlargement (13.6%) sat higher in that table. Flushes at 10.4% beat abdominal-pelvic discomfort (5.5%), nausea and vomiting (2.2%), and breast discomfort (2.1%).
Visual symptoms sat at 1.5%, headache 1.3%, abnormal uterine bleeding 1.3%. Those are separate rows. A flush is not a scotoma.
06Why a flush is not a failed 50 mg course
The goal is ovulation 5 to 10 days after the five swallows. Vasomotor heat during the tablets does not announce that the follicle failed. It also does not announce success.
Judge the course with the tests the clinic named. The wait probe is that clock.